Figure 1 | British Journal of Cancer

Figure 1

From: Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT)

Figure 1

In the first stage of ADEPT, the intravenously administered antibody–enzyme fusion protein MFECPHis is allowed to localise in the tumour. In the second stage, prodrug ZD2767P, based on a bis-iodo-phenol mustard is given after clearance of enzyme from the circulation. CP cleaves the glutamate moiety to generate the active drug ZD2767D.

Back to article page